help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johansson, A. G.
Right arrow Articles by Burman, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johansson, A. G.
Right arrow Articles by Burman, P.
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 6 2002-2007
Copyright © 1999 by The Endocrine Society


Original Studies

Gender Differences in the Effects of Long Term Growth Hormone (GH) Treatment on Bone in Adults with GH Deficiency1

Anna G. Johansson, Britt Edén Engström, Sverker Ljunghall, F. Anders Karlsson and Pia Burman

Department of Medical Sciences, University Hospital, S-751 85 Uppsala, Sweden

Address all correspondence and requests for reprints to: Anna G. Johansson, M.D., Ph.D., Department of Medical Sciences, University Hospital, S-751 85 Uppsala, Sweden. E-mail: anna.johansson{at}medicin.uu.se


    Abstract
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
We recently observed that among patients with GH deficiency due to adult-onset hypopituitarism, men responded with a greater increase in serum levels of insulin-like growth factor I (IGF-I) and biochemical markers of bone metabolism than women when the same dose of recombinant human GH (rhGH) per body surface area was administered for 9 months. In the present study, 33 of the 36 patients in the previous trial (20 men and 13 women) continued therapy for up to 45 months. The dose of rhGH was adjusted according to side-effects and to maintain serum IGF-I within the physiological range. This resulted in a significant dose reduction in the men; consequently, the women received twice as much rhGH as the men (mean ± SD, 1.9 ± 1.1 vs. 1.0 ± 0.6 U/day; P < 0.01). The increases in serum IGF-I levels and serum biochemical markers of bone metabolism were similar in men and women with these doses. The total bone mineral content (BMC) was increased after 33 and 45 months of treatment up to 5.1% (P = 0.004 and 0.0001). Bone mineral density (BMD), BMC, and the area of the femoral neck and the lumbar spine were also significantly increased after 33 and 45 months of treatment. When analyzed by gender, total body BMC, femoral neck BMD and BMC, and spinal BMC were significantly increased in males, but not in females (P < 0.05–0.01). In conclusion, rhGH treatment continued to have an effect on bone metabolism and bone mass for up to 45 months of therapy. The changes in bone mass were greater in the men, although they received lower doses of rhGH than the women. The results indicate that the sensitivity to GH in adult patients with GH deficiency is gender dependent.


    Introduction
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
IN CHILDREN, GH promotes longitudinal bone growth either by direct stimulation of cells of the chondroblastic lineage at the epiphyseal plate or by enhancement of the local production of insulin-like growth factor I (IGF-I) (1). During recent years, it has been acknowledged that GH also may serve to maintain bone mass throughout life. Adult patients with multiple pituitary insufficiency as well as those with isolated GH deficiency (GHD) are often osteopenic (2, 3, 4, 5, 6, 7, 8), and an increased risk of fractures has been reported in such patients (9, 10).

GH treatment in adults is accompanied by increased bone turnover, as reflected in the serum and urine by an elevation of biochemical markers for bone metabolism (11, 12, 13). After long term treatment, an accretion of bone mineral has been demonstrated, although the reported effects are not entirely congruent (14, 15, 16, 17, 18, 19, 20). A duration of treatment with GH of at least 18 months seems to be necessary before any increase in bone mineral content (BMC) or bone mineral density (BMD) can be detected. Recent data have shown that men with GHD are more responsive to recombinant human GH (rhGH) treatment than women with respect to changes in body composition and lipid metabolism (21), but few studies have addressed the possibility of gender as a prognostic factor for the effects on bone mass. One recent study has indicated that in terms of gain in bone density during GH replacement, women are more favored (19).

In the present study we have assessed the effects of long term treatment with rhGH on bone metabolism and bone mineral density in men and women with GHD. The male and female subgroups were similar with respect to the duration, severity, and age at onset of the disease.


    Subjects and Methods
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Patients

A total of 36 patients (15 women and 21 men) participated in the placebo-controlled part of the study. Baseline characteristics are given in Table 1Go. GH secretion was evaluated as previously reported (23), and no patient had a GH response greater than 3 µg/L during insulin-induced hypoglycemia (blood glucose, 2.2 mmol/L). Men and women differed with regard to baseline serum levels of IGF-I (Table 1Go), as previously reported (21). All patients had at least one other pituitary deficiency, and in all patients but two hypopituitarism was acquired in adulthood. Eight of the women were receiving estrogen replacement therapy (oral administration, n = 4; transdermal administration, n = 4), and all men were receiving testosterone. The women who were receiving estrogen replacement were younger than those who did not [median age: estrogen replacement, 43 yr (range, 37–52); no estrogen replacement, 52 yr (range, 45–57); P = 0.01]. Other deficiencies were being adequately replaced with levothyroxine, adrenal steroids, and (nine cases) desmopressin. All replacement treatment had been stable for at least 6 months before inclusion and was not changed during the study. None of the patients had previously received GH.


View this table:
[in this window]
[in a new window]
 
Table 1. Baseline characteristics of the patients with adult-onset GHD included in the study

 
Study protocol

An outline of the study protocol is shown in Fig. 1Go. The patients were randomized to treatment with GH or placebo for 9 months, and after 3 months of wash-out the other treatment was given for an additional 9 months. Thereafter, 33 patients chose to continue in an open study with GH treatment for up to a total of 45 months, i.e. 36 months in addition to the initial 9 months of the placebo-controlled study (Fig. 1Go). The mean dose of rhGH (Norditropin, Novo Nordisk A/S, Copenhagen, Denmark) was 1.25 U/m2 at the end of the placebo-controlled part of the study, after which the dose was adjusted according to the patient’s report of side-effects and to the serum concentration of IGF-I to maintain this within the normal reference range for the relevant age group. Injections of rhGH or placebo were given sc at bedtime by the patients themselves.



View larger version (15K):
[in this window]
[in a new window]
 
Figure 1. Study of the effects of GH therapy on bone. An initial placebo-controlled cross-over study of 18 + 18 patients with adult-onset GHD was followed by an open study of GH treatment in 33 of the patients.

 
Measurements of BMD and BMC of the total body were performed at baseline, after the first 9 months of treatment with GH or placebo, after 3 months of wash-out, and after the next 9 months of treatment with GH or placebo. Thereafter, bone mineral measurements of the total body, lumbar spine, and hip were carried out every 6 months up to a total of 33 months of GH therapy. Physical examinations were performed, and serum and urine samples were collected after an overnight fast at the same time points. Additional bone mineral measurements were carried out after a total of 45 months of GH treatment (Fig. 1Go).

The study design was approved by the Swedish Medical Products Agency and the ethical committee of the Faculty of Medicine, University of Uppsala (Uppsala, Sweden). The patients gave their informed consent to participate in the study and were told of their right to discontinue treatment at any time.

Bone mineral measurements

BMD and BMC were determined by dual energy x-ray absorptiometry (DXA; DPX-L equipment from Lunar Corp., Madison, WI) of the total body, the lumbar spine (vertebrae L2–L4; antero-posterior projection), and the femoral neck. The area of the femoral neck within a box of 12 x 50 mm and the area of the L2–L4 segment were also determined. The same box size was used for all neck analyses, and the same height of the L2–L4 vertebral segment was used for all spine evaluations via the compare scan mode. All analyses were performed by the same investigator (A.G.J.) at the end of the study. The coefficient of variation for DXA was less than 1%. The reference values provided by the manufacturer were used to calculate t-scores, which express individual BMD values as SD scores in relation to the normal mean and variation in BMD values in healthy young men or women (20–45 yr old in the femur reference group and 20–40 yr old in the antero-posterior spine reference group), and age-, sex-, and weight-adjusted z-scores.

At baseline, the t-score for total body BMD was for all patients -0.47 ± 1.02 (range, -2.74 to 1.34); for the men it was -0.62 ± 0.94, and for the women it was -0.24 ± 1.12 (P = 0.33 for difference between genders). The z-score at baseline for total body BMD was -0.39 ± 0.93 (range, -2.79 to 1.42) for the whole patient group, -0.36 ± 0.89 for the men and -0.44 ± 1.03 for the women (P = 0.83 for difference between genders). After 15 months of GH treatment, when the first DXA measurements of the hip and the spine were performed (Fig. 1Go), the t-score for the femoral neck was -0.75 ± 1.00 (-2.58 to 1.03) for all patients, -0.83 ± 1.17 for the male patients, and -0.62 ± 0.67 for the female patients (P = 0.64 for difference between genders). The z-score for the femoral neck was -0.35 ± 1.01 (range, -2.56 to 1.19) for all subjects, -0.44 ± 1.15 for the men, and -0.18 ± 0.74 for the women (P = 0.57 for difference between genders). The t-score for the lumbar spine (L2-L4) was -1.0 ± 1.20 (range, -3.16 to 1.99) for all patients, -0.74 ± 1.15 for the men, and -1.46 ± 1.22 for the women (P = 0.18 for difference between genders). The z-score for the lumbar spine (L2–L4) was -0.60 ± 1.18 (range, -2.18 to 2.31) for all patients, -0.35 ± 1.13 for the men, and -1.04 ± 1.20 for the women (P = 0.19 for difference between genders).

Biochemical analyses

Osteocalcin concentrations were determined in fasting morning serum by RIA with a commercial kit (CIS-Bio International, Oris Industries, Gif-Sur-Yvette, France). The intra- and interassay variations were less than 7%, and the reference range was 5–15 µg/L. Serum IGF-I was measured with a commercial RIA (Nichols Institute Diagnostics, San Juan Capistrano, CA) after extraction of binding proteins with acid-ethanol. The reference ranges in relevant age groups were 150–450 µg/L (20–40 yr) and 100–340 µg/L (41–60 yr). Plasma GH was assayed with a polyclonal RIA, with the lowest level of detection at 0.3 µg/L and intra- and interassay variations below 8%.

Statistics

Values are expressed as the mean ± SD in tables and as the mean ± SEM in figures. Student’s paired t test was used to test for changes within groups, and the unpaired t test was used for gender comparisons at 33 months. To limit the number of comparisons, paired comparisons with the baseline measurement were performed with the last time point of the treatment periods in the placebo-controlled study and with the last two time points of the follow-up study (study months 33 and 45).


    Results
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
BMD and BMC changes during treatment with GH

In the patients who received rhGH during the first 9 months, total body BMD was significantly decreased at the end of this period and then returned to baseline during the following placebo period (Fig. 2Go). In the patients who received placebo first, total body BMD did not change until they received rhGH treatment. During the following open treatment with rhGH up to a total of 45 months (n = 16), total body BMD in the whole group of patients showed no significant change compared to baseline.



View larger version (35K):
[in this window]
[in a new window]
 
Figure 2. Changes in total BMD (top) and BMC (bottom) compared to baseline during treatment with rhGH or placebo (pl; dotted line) in patients with GHD. Squares represent patients who received GH first and then placebo (GH/pl), and circles represent patients with the reverse treatment order (pl/GH). The shaded area indicates the 3-month wash-out period (w-o) before cross-over. *, P < 0.05; **, P < 0.01 (significant difference compared to baseline). Symbols and vertical bars denote the mean ± SEM.

 
Total body BMC was increased after a total of 15 months of treatment in the group that received rhGH during the first 9 months of the study (Fig. 2Go). There was also a tendency for an increase in total body BMC after 15 months in the group that received rhGH during the second 9-month period (P = 0.06). After a total of 45 months of treatment with rhGH, the mean increase in total body BMC in the whole group of patients was 5.1 ± 3.9% compared to baseline (P = 0.0001).

Femoral neck BMD was increased in the whole group of patients by 6.7% from 15–45 months of treatment with rhGH (Table 2Go). BMC and the area of the femoral neck also increased during this period of treatment. In the spine, BMD was significantly increased, and concomitant increases in BMC and the area of the L2–L4 vertebrae were observed after 33 and 45 months of treatment with rhGH (Table 2Go) compared to values at 15 months.


View this table:
[in this window]
[in a new window]
 
Table 2. Changes (percentage) in bone densitometry variables of the femoral neck and lumbar spine in patients with GHD treated with rhGH

 
There were no significant linear correlations between baseline BMD and the changes after GH treatment.

Gender differences in response to GH treatment

On completion of the placebo-controlled period, the dose of GH adjusted for body surface area was similar in men and women (21) (Fig. 3Go). At this point the increase in serum IGF-I was greater in men than in women (308 ± 133 vs. 206 ± 91 µg/L; P = 0.02). During the following open study phase the dose was adjusted as described, and by this procedure the doses were lowered, particularly in the male patients. This resulted in a dose approximately 2 times higher in the women than in the men, with total daily doses of 1.9 ± 1.1 and 1.0 ± 0.6 U, respectively, after a total of 33 months of GH treatment (Fig. 3Go). Despite this, the increase in serum IGF-I compared to the baseline level was similar in the men and women (Fig. 3Go). The doses given to women receiving and not receiving estrogen did not differ at any time point during the study. Serum IGF-I at baseline was 62 ± 39 µg/L in women receiving estrogen and 60 ± 29 µg/L in women who did not. The increase in serum IGF-I during treatment was similar in the two groups of women.



View larger version (19K):
[in this window]
[in a new window]
 
Figure 3. Dose of rhGH in relation to body surface area (top) and changes in serum IGF-I (middle) and serum osteocalcin (bottom) during the study period in men (open circles) and women (filled squares) with GH compared to pretreatment values. *, P < 0.05; **, P < 0.01 (significant difference between genders). Symbols and vertical bars denote the mean ± SEM.

 
The serum concentrations of osteocalcin increased more in the men than in women when the same dose of rhGH per body surface area was administered, but to the same extent in men and women when adjusted doses of rhGH were used (Fig. 3Go). As previously reported, the increments in the other serum markers of bone formation [bone alkaline phosphatase and procollagen type I C-peptide (PICP)] and bone resorption [telopeptide of collagen type I (ICTP)] also differed between men and women given the same dose during the blinded study phase (21), but there was no difference between the male and female patients during the open study phase (data not shown).

The changes in BMD and BMC were analyzed with respect to gender after 33 months of GH treatment, i.e. 24 months after individual dose adjustments based on IGF-I and/or side-effects. It was found that the total body BMC, femoral neck BMD and BMC, and spine BMC had increased significantly in the men but not in the women (Fig. 4Go).



View larger version (13K):
[in this window]
[in a new window]
 
Figure 4. Changes in BMD and BMC in men (open columns) and women (filled columns) with GHD after 33 months of treatment with rhGH compared to baseline values (total body BMD and BMC; n = 33, 20 men) and to values obtained after 15 months of treatment (femoral neck and spinal BMC and BMD; n = 18, 11 men). *, P < 0.05; **, P < 0.01 (significant difference compared to baseline). Columns and vertical bars denote the mean ± SEM.

 

    Discussion
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
In the present study we observed increases in BMD and BMC at different measurement sites during long term treatment with rhGH in patients with hypopituitarism. The male patients with GHD gained more from the long term GH treatment with regard to bone mass despite receiving significantly lower doses of rhGH than the women. Furthermore, there were sustained increases in serum markers of bone metabolism and in serum IGF-I; these changes were similar in the men and women despite the difference in rhGH dose.

There is both clinical and experimental support for an interaction between sex hormones and GH at the peripheral level. GH replacement therapy in young men with childhood-onset GHD has been observed to stimulate the growth of androgen-dependent body hair without a concomitant change in circulating levels of free testosterone (22). This report corroborates an early finding that the dose of androgen required to induce secondary sex characteristics in sexually immature boys was significantly higher in GH-deficient than in GH-sufficient individuals (23). These observations suggest that androgens may potentiate the effects of GH. In contrast, administration of estrogens to postmenopausal women decreases the serum concentrations of IGF-I (24, 25), and high doses of estrogens were previously used to alleviate symptoms and metabolic effects in acromegalic patients (26). The similar serum concentrations of IGF-I in healthy men and women despite a 2- to 3-fold higher secretion of GH in women (27, 28, 29) also suggest an antagonism between GH and estrogen at the target site.

In castrated rabbits the expression of GH receptor messenger ribonucleic acid in both the liver and the growth plate has been reported to be increased by testosterone and decreased by estradiol (30). This could be a mechanism responsible for the gender difference in the serum IGF-I response to GH treatment and could be of relevance for the present finding of a greater gain in bone mass in the GHD men. On the other hand, in rats estradiol has been found to stimulate GH receptor expression (31), and testosterone did not influence GH-induced IGF-I expression (32). Osteoblasts contain receptors for both androgens and estrogens (33), and in bone cells, estradiol stimulated GH receptor expression (34). The discrepant results could be explained by tissue or species differences.

In several previous investigations of the effects of rhGH on bone density the results have varied markedly. In general, the studies in which more substantial increases in BMD have been found have included a relatively larger proportion of men than women (14, 15, 16, 18, 20, 35, 36, 37). The report of a significant difference in the change in total body BMD in women than in men with rhGH for 2 yr (19) remains to be explained, in particular as total body BMD was not significantly altered from baseline, and the difference seems to be due to on an initial reduction in total body BMD in the male patients. Furthermore, no gender difference was found when assessments were made in the hip and spine, regions that, in general, respond more to treatment with GH than total bone (19, 20).

When comparing the effects of GH on bone in men and women, other factors have to be accounted for, such as the severity of osteopenia, concomitant medication or other diseases that might modulate bone density, and also differences in hydrocortisone and thyroid replacement therapy. Although men and women were not stratified for possible confounding factors, there were no apparent differences between the two groups, and the number of women receiving estrogen as pills or patches were similar. The z and t-scores for BMD were not statistically different between men and women. However, contrary to another report (19), we did not find a relation between the severity of osteopenia per se, and bone density changes during treatment. Two of the men had onset of GHD during adolescence, but their bone densities were not more pronounced than those in the other patients; furthermore, one of them did not participate in the open study phase. In women, the route of estrogen administration (oral vs. transdermal) may also influence the GH/IGF-I axis (24).

Similar to Johannsson et al. (19), we did not detect a difference in bone acquisition or in markers of bone metabolism between women with and without estrogen replacement (data not shown). As the women had low androgen levels due to lack of stimulation of the adrenals, this might suggest that the combined effect of GH and testosterone is more important than an interaction between GH and estrogens. However, an evaluation of the impact of female sex steroids was hampered by the small number of women in each group and the fact that the women not receiving estrogen were older.

In a study of adult GHD men in whom bone histology was investigated after 12 months of treatment with rhGH, both the number of osteoclasts and the cortical thickness were increased, but trabecular bone volume did not change after the treatment (38). This is compatible with the finding in experimental animals that GH increases cortical thickness and has the potential to increase bone size (39, 40), possibly by enhancing periosteal bone formation. Indeed, an increased projected bone area was observed during treatment with rhGH in the present study in both the spine and hip. Such an increase in bone size may be expected to synergize with increased bone density with regard to bone strength.

In the present study, we found a reduction in BMD during the initial 9-month period of the treatment. Similar findings have previously been reported by others (12, 15, 17, 18, 36, 41, 42, 43, 44). The popular theory that this is due to an expansion of the remodeling space as a result of an increased activation frequency is corroborated by the histomorphometric findings of Bravenboer et al. (38). The complete restoration of total body BMD in the present study during wash-out and placebo treatment is compatible with that theory. If the rhGH treatment primarily increases periosteal bone formation, this could contribute to a reduction in areal bone density, as newly formed bone has a lower mineral density than older bone (45), but still increase the projected bone area.

In conclusion, the present study indicates a progressive gain in BMD and BMC during treatment with rhGH for as long as 45 months. A gender difference in the sensitivity to GH is demonstrated by similar increases in serum levels of IGF-I and bone biomarkers in the men and women despite 2-fold higher doses in the women and also by a more marked gain in bone mass in the men during long term treatment. To further clarify the impact of sex hormones on the effects of GH on bone, a controlled study including large numbers of GHD women with and without estrogen replacement therapy is awaited.


    Acknowledgments
 
The skillful technical assistance of Eva-Britt Borgestig, R.N., is greatly appreciated. Drs Eva-Marie Erfurth and Erik Hägg are gratefully acknowledged for referring some of the patients.


    Footnotes
 
1 This work was supported by Novo Nordisk Pharma AS (Copenhagen, Denmark) and the Swedish Medical Research Council (Project 4996). Back

Received July 10, 1998.

Revised December 2, 1998.

Revised February 24, 1999.

Accepted March 1, 1999.


    References
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Nilsson A, Isgaard J, Lindahl A, Dahlström A, Skottner A, Isaksson OGP. 1986 Regulation by growth hormone of number of chondrocytes containing IGF-I in rat growth plate. Science. 233:571–574.[Abstract/Free Full Text]
  2. Johansson AG, Burman P, Westermark K, Ljunghall S. 1992 The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I. J Intern Med. 232:447–452.[Medline]
  3. Kaufman J-M, Taelman P, Vermeulen A, Vandeweghe M. 1992 Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab. 74:118–123.[Abstract]
  4. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. 1994 Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab. 78:669–674.[Abstract]
  5. Rosén T, Hansson T, Granhed H, Szucs J, Bengtsson B-Å. 1993 Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 129:201–206.[Medline]
  6. Bing-You RG, Denis M-C, Rosen CJ. 1993 Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3. Calcif Tissue Int. 52:183–187.[CrossRef][Medline]
  7. De Boer H, Blok GJ, Van Lingen A, Teule GJJ, Lips P, van der Veen EA. 1994 Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res. 9:1319–1326.[Medline]
  8. Degerblad M, Elgindy N, Hall K, Sjöberg H-E, Thorén M. 1992 Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocrinol (Copenh). 126:387–393.[Abstract/Free Full Text]
  9. Wüster C, Slenczka E, Ziegler R. 1991 Increased prevalence of osteoporosis and arteriosclerosis in patients with conventionally substituted pituitary insufficiency: is there a need for additional growth hormone substitution? Klin Wochenschr. 69:769–773.[CrossRef][Medline]
  10. Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson B-Å. 1997 Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol. 137:240–245.[Abstract]
  11. Nielsen HK, Jørgensen JOL, Brixen K, Christiansen JS. 1991 Serum osteocalcin and bone isoenzyme alkaline phosphatase in growth hormone-deficient patients: dose-response studies with biosynthetic human GH. Calcif Tissue Int. 48:82–87.[Medline]
  12. Binnerts A, Swart GR, Wilson JHP, Hoogerbrugge N, Pols HAP, Birkenhager JC, Lamberts SWJ. 1992 The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol (Oxf). 37:79–87.[Medline]
  13. Beshyah SA, Thomas E, Kyd P, Sharp P, Fairney A, Johnston DG. 1994 The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism. Clin Endocrinol (Oxf). 40:383–391.[Medline]
  14. Baum HBA, Biller BMK, Finkelstein JS, et al. 1996 Effects of physiological growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. Ann Intern Med. 125:883–890.[Abstract/Free Full Text]
  15. Vandeweghe M, Taelman P, Kaufman J-M. 1993 Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol (Oxf). 39:409–415.[Medline]
  16. Amato G, Izzo G, La Montagna G, Bellastella A. 1996 Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects. Clin Endocrinol (Oxf). 45:27–32.[CrossRef][Medline]
  17. Hansen TB, Brixen K, Vahl N, Jørgensen JOL, Christiansen JS, Mosekilde L, Hagen C. 1996 Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab. 81:3352–3359.[Abstract]
  18. Holmes SJ, Whitehous RW, Swindell R, Economou G, Adams JE, Shalet SM. 1995 Effect of growth hormone replacement on bone mass in adult onset growth hormone deficiency. Clin Endocrinol (Oxf). 42:627–633.[Medline]
  19. Johannsson G, Rosén T, Bosaeus I, Sjöström L, Bengtsson B-Å. 1996 Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab. 81:2865–2873.[Abstract/Free Full Text]
  20. Finkenstedt G, Gasser R W, Höfle G, Watfah C, Fridrich L. 1997 Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up. Eur J Endocrinol. 136:282–289.[Abstract/Free Full Text]
  21. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA. 1997 Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab. 82:550–555.[Abstract/Free Full Text]
  22. Blok GJ, de Boer H, Gooren LJG, van der Veen EA. 1997 Growth hormone substitution in adult growth hormone deficient men augments androgen effects on the skin. Clin Endocrinol (Oxf). 47:29–36.[CrossRef][Medline]
  23. Zachmann M, Prader A. 1970 Anabolic and androgenic effect of testosterone in sexually immature boys and its dependency on growth hormone. J Clin Endocrinol Metab. 30:85–95.[Abstract/Free Full Text]
  24. Weissberger AJ, Ho KY, Lazarus L. 1991 Contrasting effects of oral and transdermal routes of replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor 1, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 72:374–381.[Abstract/Free Full Text]
  25. Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO. 1996 Both oral and transdermal estrogen increase growth hormone release in postmenopausal women. J Clin Endocrinol Metab. 81:2250–2256.[Abstract]
  26. Clemmons DR, Underwood LE, Ridgay EC, Kliman B, Kjellberg RN, Van Wyk JJ. 1980 Estradiol treatment of acromegaly: reduction of immunoreactive somatomedin C and improvement of metabolic status. Am J Med. 69:571–575.[CrossRef][Medline]
  27. Ho KY, Evans WS, Blizzard RM, et al. 1987 Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab. 64:51–58.[Abstract/Free Full Text]
  28. Van den Berg G, Veldhuis JD, Frölich Marijke, Roelfsema F. 1996 An amplitude-specific divergence in the pulsatile mode of growth hormone secretion underlies the gender difference in mean GH concentration in men and premenopausal women. J Clin Endocrinol Metab. 81:2460–2467.[Abstract]
  29. Veldhuis JD. 1996 Gender differences in secretory activity of the human somatropic (growth hormone) axis. Eur J Endocrinol. 134:287–295.[Abstract/Free Full Text]
  30. Yu YM, Domené HM, Sztein J, Counts DR, Cassoria F. 1996 Developmental changes and differential regulation by testosterone and estradiol of growth hormone receptor expression in the rabbit. Eur J Endocrinol. 135:583–589.[Abstract/Free Full Text]
  31. Carmignac DF, Gabrielsson BG, Robinson ICAF. 1993 Growth hormone binding proteins in the rat: effects of gonadal steroids. Endocrinology. 133:2445–2452.[Abstract/Free Full Text]
  32. Phillip M, Palese T, Hernandez ER, Roberts CT, LeRoith D, Kowarski AA. 1992 Effect of testosterone on insulin-like growth factor-I (IGF-I) and IGF-I receptor gene expresion in the hypophysectomized rat. Endocrinology. 130:2865–2870.[Abstract/Free Full Text]
  33. Manolagas SC, Jilka RL. 1995 Bone marrow, cytokines, and bone remodeling. N Engl J Med. 332:305–311.[Free Full Text]
  34. Slootweg MC, Swolin D, Netelenbos JC, Isaksson OGP, Ohlsson C. 1997 Estrogen enhances growth hormone receptor expression and growth hormone action in rat osteosarcoma cells and human osteoblast-like cells. J Endocrinol. 155:159–164.[Abstract/Free Full Text]
  35. O’Halloran DJ, Tsatsoulis A, Whitehouse RW, Holmes SJ, Adams JE, Shalet SM. 1993 Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab. 76:1344–1348.[Abstract]
  36. Rosén T, Johannsson G, Hallgren P, Caidahl K, Bosaeus I, Bengtsson B-Å. 1994 Beneficial effects of 12 months replacement therapy with recombinant human growth hormone to growth hormone deficient adults. Endocrinol Metab. 1:55–66.
  37. Juul A, Pedersen SA, Sørensen S, Winkler K, Jørgensen JOL, Christiansen JS, Skakkebæk NE. 1994 Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset. Eur J Endocrinol. 131:41–49.[Abstract/Free Full Text]
  38. Bravenboer N, Holzmann P, De Boer H, Roos JC, Van der Veen EA, Lips P. 1997 The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men. J Clin Endocrinol Metab. 82:1818–1822.[Abstract/Free Full Text]
  39. Andreassen TT, Jørgensen PH, Flyvbjerg A, Ørskov H, Oxlund H. 1995 Growth hormone stimulates bone formation and strength of cortical bone in aged rats. J Bone Miner Res. 10:1057–1067.[Medline]
  40. Andreassen TT, Melsen F, Oxlund H. 1996 The influence of growth hormone on cancellous and cortical bone of the vertebral body in aged rats. J Bone Miner Res. 11:1094–1102.[Medline]
  41. Degerblad M, Bengtsson B-Å, Bramnert M, Johnell O, Manhem P, Rosén T, Thorén M. 1995 Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy. Eur J Endocrinol. 133:180–188.[Abstract/Free Full Text]
  42. Cuneo RC, Judd S, Wallace JD, et al. 1998 The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab. 83:107–116.[Abstract/Free Full Text]
  43. Weaver JU, Monson JP, Noonan K, et al. 1996 The effect of low dose recombinant human growth hormone replacement on indices of bone remodelling and bone mineral density in hypopituitary growth hormone-deficient adults. Endocrinol Metab. 3:55–61.
  44. Thorén M, Soop M, Degerblad M, Sääf M. 1993 Preliminary study of the effects of growth hormone substitution therapy on bone mineral density and serum osteocalcin levels in adults with growth hormone deficiency. Acta Endocrinol (Copenh). 128(Suppl 2):41–43.
  45. Meunier PJ, Boivin G. 1997 Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone. 21:373–377.[Medline]



This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
T. Munzer, S. M. Harman, J. D. Sorkin, and M. R. Blackman
Growth Hormone and Sex Steroid Effects on Serum Glucose, Insulin, and Lipid Concentrations in Healthy Older Women and Men
J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3833 - 3841.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
O. Klefter and U. Feldt-Rasmussen
Is increase in bone mineral content caused by increase in skeletal muscle mass/strength in adult patients with GH-treated GH deficiency? A systematic literature analysis
Eur. J. Endocrinol., August 1, 2009; 161(2): 213 - 221.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Glaser, N. Friedrich, R. Ewert, C. Schaper, M. Nauck, M. Dorr, H. Volzke, S. B. Felix, A. Krebs, H. Wallaschofski, et al.
Association between Serum Insulin-Like Growth Factor (IGF) I and IGF Binding Protein-3 and Lung Function
J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2452 - 2458.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
A. Giustina, G. Mazziotti, and E. Canalis
Growth Hormone, Insulin-Like Growth Factors, and the Skeleton
Endocr. Rev., August 1, 2008; 29(5): 535 - 559.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
A. A van der Klaauw, N. R Biermasz, P. M J Zelissen, A. M Pereira, E. G W M Lentjes, J. W A Smit, S. W van Thiel, J. A Romijn, and F. Roelfsema
Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism
Eur. J. Endocrinol., December 1, 2007; 157(6): 709 - 716.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
R. N. Dhir, C. Thangavel, and B. H. Shapiro
Attenuated Expression of Episodic Growth Hormone-Induced CYP2C11 in Female Rats Associated with Suboptimal Activation of the Jak2/Stat5B and Other Modulating Signaling Pathways
Drug Metab. Dispos., November 1, 2007; 35(11): 2102 - 2110.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. Thangavel and B. H. Shapiro
A Molecular Basis for the Sexually Dimorphic Response to Growth Hormone
Endocrinology, June 1, 2007; 148(6): 2894 - 2903.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. Sathiavageeswaran, P. Burman, D. Lawrence, A. G Harris, M. G Falleti, P. Maruff, and J. Wass
Effects of GH on cognitive function in elderly patients with adult-onset GH deficiency: a placebo-controlled 12-month study
Eur. J. Endocrinol., April 1, 2007; 156(4): 439 - 447.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
G Gotherstrom, B-A Bengtsson, I Bosaeus, G Johannsson, and J Svensson
Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency
Eur. J. Endocrinol., January 1, 2007; 156(1): 55 - 64.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Parkinson, P. Burman, M. Messig, and P. J. Trainer
Gender, Body Weight, Disease Activity, and Previous Radiotherapy Influence the Response to Pegvisomant
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 190 - 195.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
S Pekic, M Doknic, D Miljic, M Joksimovic, J Glodic, M Djurovic, C Dieguez, F Casanueva, and V Popovic
Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
Eur. J. Endocrinol., May 1, 2006; 154(5): 659 - 666.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
Y. Wang, T. Sakata, H. Z Elalieh, S. J Munson, A. Burghardt, S. Majumdar, B. P Halloran, and D. D Bikle
Gender differences in the response of CD-1 mouse bone to parathyroid hormone: potential role of IGF-I.
J. Endocrinol., May 1, 2006; 189(2): 279 - 287.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. N. Dhir, W. Dworakowski, C. Thangavel, and B. H. Shapiro
Sexually Dimorphic Regulation of Hepatic Isoforms of Human Cytochrome P450 by Growth Hormone
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 87 - 94.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Colao, C. Di Somma, A. Cuocolo, L. Spinelli, W. Acampa, S. Spiezia, F. Rota, M. C. Savanelli, and G. Lombardi
Does a Gender-Related Effect of Growth Hormone (GH) Replacement Exist on Cardiovascular Risk Factors, Cardiac Morphology, and Performance and Atherosclerosis? Results of a Two-Year Open, Prospective Study in Young Adult Men and Women with Severe GH Deficiency
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5146 - 5155.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. R. Hoffman, J. E. Kuntze, J. Baptista, H. B. A. Baum, G. P. Baumann, B. M. K. Biller, R. V. Clark, D. Cook, S. E. Inzucchi, D. Kleinberg, et al.
Growth Hormone (GH) Replacement Therapy in Adult-Onset GH Deficiency: Effects on Body Composition in Men and Women in a Double-Blind, Randomized, Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2048 - 2056.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Gillberg, H. Mallmin, M. Petren-Mallmin, S. Ljunghall, and A. G. Nilsson
Two Years of Treatment with Recombinant Human Growth Hormone Increases Bone Mineral Density in Men with Idiopathic Osteoporosis
J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4900 - 4906.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
E. F. Gevers, N. Loveridge, and I. C. A. F. Robinson
Bone Marrow Adipocytes: A Neglected Target Tissue for Growth Hormone
Endocrinology, October 1, 2002; 143(10): 4065 - 4073.
[Abstract] [Full Text] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
R. N. Butler, M. Fossel, S. M. Harman, C. B. Heward, S. J. Olshansky, T. T. Perls, D. J. Rothman, S. M. Rothman, H. R. Warner, M. D. West, et al.
Is There an Antiaging Medicine?
J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2002; 57(9): B333 - 338.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
W. L. Isley
Growth Hormone Therapy for Adults: Not Ready for Prime Time?
Ann Intern Med, August 6, 2002; 137(3): 190 - 196.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Gotherstrom, J. Svensson, J. Koranyi, M. Alpsten, I. Bosaus, B.-A. Bengtsson, and G. Johannsson
A Prospective Study of 5 Years of GH Replacement Therapy in GH-Deficient Adults: Sustained Effects on Body Composition, Bone Mass, and Metabolic Indices
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4657 - 4665.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. P. T. Span, G. F. F. M. Pieters, F. G. J. Sweep, A. R. M. M. Hermus, and A. G. H. Smals
Gender Differences in rhGH-Induced Changes in Body Composition in GH-Deficient Adults
J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4161 - 4165.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet
Optimizing GH Therapy in Adults and Children
Endocr. Rev., August 1, 2001; 22(4): 425 - 450.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Munzer, S. M. Harman, P. Hees, E. Shapiro, C. Christmas, M. F. Bellantoni, T. E. Stevens, K. G. O'Connor, K. M. Pabst, C. St. Clair, et al.
Effects of GH and/or Sex Steroid Administration on Abdominal Subcutaneous and Visceral Fat in Healthy Aged Women and Men
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3604 - 3610.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. R. Biermasz, N. A. T. Hamdy, Y. J. H. Janssen, and F. Roelfsema
Additional Beneficial Effects of Alendronate in Growth Hormone (GH)-Deficient Adults with Osteoporosis Receiving Long-Term Recombinant Human GH Replacement Therapy: A Randomized Controlled Trial
J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3079 - 3085.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
E. Omerovic, E. Bollano, R. Mobini, V. Kujacic, B. Madhu, B. Soussi, M. Fu, A. Hjalmarson, F. Waagstein, and J. Isgaard
Growth Hormone Improves Bioenergetics and Decreases Catecholamines in Postinfarct Rat Hearts
Endocrinology, December 1, 2000; 141(12): 4592 - 4599.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. M. K. Biller, G. Sesmilo, H. B. A. Baum, D. Hayden, D. Schoenfeld, and A. Klibanski
Withdrawal of Long-Term Physiological Growth Hormone (GH) Administration: Differential Effects on Bone Density and Body Composition in Men with Adult-Onset GH Deficiency
J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 970 - 976.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johansson, A. G.
Right arrow Articles by Burman, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johansson, A. G.
Right arrow Articles by Burman, P.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals